Search Results 861-870 of 11274 for Antifungal Resistance
... resistant to ruxolitinib or 2) ineligible for ruxolitinib therapy, as determined by the treating Investigator. accelerated phase/blast phase MPN (MPN-AP/BP) ...
The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache ...
Measurements of antifungal levels in corneal tissue: a simplified bioassay for amphotericin B. Williams TE. T E; O'Day DM. D M; Head WS. W S; Robinson RD. R ...
Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some featured. Mayo Clinic discovery of breast cancer treatment resistance ...
Triamcinolone may lower your body's resistance and the vaccine may not work as well or you might get the infection the vaccine is meant to prevent. In ...
... fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any ...
Tande AJ, Stevens RW, Ilges D, Lahr BD, Challener DW. Cumulative antibiotic exposure is associated with ceftriaxone resistance among patients with urinary ...
About this study. This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior ...
This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical ...
Discovery of how MxB targets and regulates liver mitochondria. Dr. Cao has previously reported that myxovirus-resistance protein B (MxB), a member of the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.